Biomarker for assessing response to chymase treatment
OwnerZhiming Zhang, Michael D'Andrea +1inventors
InventorsZhiming Zhang, Michael D'Andrea, Stanley M. Belkowski
Life of this patent
Estimating the term…
Abstract
A biomarker that correlates to treatment with drugs that inhibit chymase is disclosed. This biomarker has been shown to have utility in assessing response to chymase inhibitor compounds. The immunoreactivity or levels of the biomarker is increased upon treatment with chymase inhibitor compounds, thus indicating that this biomarker is involved in chymase activity.
Claims6
A biomarker predictive of a response of cells to treatment with a drug that inhibits chymase activity.
A method of predicting whether a drug is capable of inhibiting chymase activity in a cell, comprising:
- a) obtaining a first sample of cells prior to administration of said drug, b) obtaining a second sample of cells after administration of said drug;
- c) determining the immunoreactivity of IL-18 in said first and second samples;
- d) comparing the immunoreactivity of IL-18 in said samples;
- and e) correlating any change in the immunoreactivity of IL-18 to said drugs' ability or inability to inhibit chymase activity in said subject.
A method of screening for a candidate drug capable of inhibiting the activity of chymase, comprising:
- a) contacting a test drug with a sample of cells;
- and b) selecting as a candidate those drugs that increase IL-18 in said sample of cells.
Dependencies are inferred from the claim text.